Lactic Acid Bacteria Selection for pDC-Driven Interferon Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively utilized lactic acid bacteria to activate plasmacytoid dendritic cells (pDCs) for inducing interferon production, particularly for antiviral prophylaxis, and the correlation between lactic acid bacteria and pDC activation for interferon production remains unclear.
Innovation Solution
Development of an assay system using pDC activation as an indicator to select lactic acid bacteria that potentiate antiviral prophylaxis through ingestion, specifically identifying spherical-shaped bacteria like Lactococcus lactis subsp. lactis JCM5805, which activate pDCs and induce interferon production, including type I and type III interferons, and are tolerant to gastric and intestinal juices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lactic acid bacteria are used to activate pDCs and induce interferon production, then antiviral prophylaxis is enhanced, but the correlation between lactic acid bacteria and pDC activation remains unclear
Solution Approach 1:
The patent replaces complex in vivo animal experiments with an in vitro human pDC activation assay system. This substitution allows direct measurement of interferon production in response to specific lactic acid bacteria strains, establishing clear causal correlations without the variability and ethical constraints of animal models. The assay system directly measures the relationship between bacterial stimuli and pDC activation markers.
Solution Approach 2:
The patent implements feedback mechanisms through the assay system by measuring interferon production levels and pDC activation markers as direct responses to lactic acid bacteria stimulation. This feedback loop enables identification of specific bacterial strains that effectively activate pDCs, allowing for selection and optimization of probiotic candidates based on quantifiable immunological responses.
2Quantity of substance
If spherical-shaped lactic acid bacteria like Lactococcus lactis subsp. lactis JCM5805 are used to activate pDCs, then interferon production is induced, but the bacteria must be tolerant to gastric and intestinal juices
Solution Approach 1:
The patent evaluates and selects lactic acid bacteria strains based on specific parameters including spherical shape morphology, interferon induction capability, and tolerance to gastric and intestinal juices. By changing and optimizing these parameters during strain selection, the patent identifies bacteria that can survive the harsh gastrointestinal environment while maintaining their ability to activate pDCs and induce interferon production.
3Productivity
If an assay system using pDC activation as indicator is developed to select lactic acid bacteria, then antiviral prophylaxis is potentiated, but the system complexity increases
Solution Approach 1:
The patent segments the complex in vivo animal experiment process into a simplified in vitro assay system. This segmentation isolates the critical measurement function (pDC activation and interferon production) from the complexity of whole-organism physiology, allowing for straightforward strain selection while maintaining relevance to antiviral prophylaxis effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selected lactic acid bacteria effectively activate pDCs in vivo, inducing interferon production, enhancing immune responses, and providing prophylactic and therapeutic benefits against viral infections, usable in pharmaceutical and food products.
Implementation Method 1
lactic acid bacteria capable of activating plasmacytoid dendritic cells (pDCs) and inducing IFN production
Implementation Method 2
they cause physiological reactions, such as cytokine or chemokine production
Data Source
AI summary
This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp. lactis JCM20101, Leuconostoc lactis NBRC12455, Leuconostoc lactis NRIC1540, Pediococcus damnosus JCM5886, or Streptococcus thermophilus TA-45.